Cardinal Health’s Executives Cashed Out $60 Million at Record Highs. Wall Street Still Won’t Blink.

Posted on by

(SeaPRwire) –   By: Robert Kensington

The smartest money doesn’t always signal its intentions. Cardinal Health just proved that again. Its C-suite quietly unloaded nearly $60 million in stock right after posting one of the strongest quarters in recent memory. That’s not a red flag. That’s a flashing strobe light.

The numbers don’t lie. Earnings per share of $2.91 smashed through the $2.42 consensus estimate. Revenue came in at $63.67 billion. That’s a 5.8% increase year over year. The company guided toward $12.40 to $12.60 in full-year 2027 EPS. Wall Street loved it. The stock hit $240.26 on August 11th and touched $258.30 intraday. The insiders watched the tape, and they sold.

CEO Jason Hollar moved first. He dumped 124,529 shares for $29.4 million on August 18th. This was his first open-market sale since August 2025. His second since joining Cardinal in 2020. CFO Aaron Alt sold 42,000 shares for $9.9 million. Jessica Mayer, the chief legal and compliance officer, offloaded 29,436 shares for nearly $7 million. Michelle Greene, the CIO, sold 11,650 shares for $2.7 million. Steve Mason, CEO of the global medical products and distribution segment, cut his ownership stake by 66%. He took $8.3 million off the table. Debbie Weitzman, running the pharmaceutical unit, sold $1.7 million worth. Mary Scherer, the chief accounting officer, cashed out $546,472 on August 19th. The total across all insiders came to 210,271 shares worth nearly $49.6 million last quarter. All of this happened at prices between $234.07 and $238.065 per share.

Let me be clear about what that means. These are not routine diversification plays. This is coordinated selling at elevated prices by people who understand exactly where this stock sits in the cycle. They just delivered a blowout quarter. They set guidance well above consensus. And they sold into the rally. I’ve seen this playbook before in industrial supply chains where margin pressures lurk beneath glossy earnings beats. The numbers look clean on paper. The cash flow tells a different story.

Meanwhile, analysts are still calling for $266 to $292. TD Cowen raised its target to $280 with a buy rating. Leerink set $292. RBC initiated at $276 with an outperform. JPMorgan is the outlier here. They raised their target from $215 to $260 but downgraded to neutral. That downgrade matters more than the price target increase. JPMorgan sees something the others don’t. The stock opened at $229.48 on Friday after that intraday high of $258.30. It’s still up significantly from the $145.87 twelve-month low, but the recent pullback from the highs tells the real story. The market is starting to price in what the insiders already knew.

The dividend is a nice touch. $0.5158 per share quarterly. A 0.9% yield. That’s the kind of signal a company sends when it wants to project stability. But dividends don’t replace cash flow. They distract from it. Cardinal’s stock might retest the $230 level before finding real support. The insiders aren’t looking for a longer hold. They’re looking for an exit window. The market hasn’t figured that out yet. That window won’t stay open forever.

Author bio: Robert Kensington is an overseas entrepreneurial veteran with decades of experience in real-economy industrial investment and expansion. He has advised private equity firms and Fortune 500 industrial supply chain executives on market cycles and insider behavior.